Yamanaka Taro, Nishikawa Tadaaki, Yoshida Hiroshi
Department of Medical Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo 105-8461, Japan.
Cells. 2025 Feb 24;14(5):333. doi: 10.3390/cells14050333.
Despite recent advances in cancer treatment, the prognosis for uterine malignancies (carcinoma and sarcoma) requires further improvement. Antibody-drug conjugates (ADCs) have emerged as a novel class of anti-cancer therapeutic agents, and multiple ADCs have been approved for other types of cancer. In 2024, trastuzumab deruxtecan received approval from the US Food and Drug Administration for cancer types and became the first ADC approved for the treatment of uterine malignancies. Many ADCs are currently being investigated in uterine malignancies, and therefore, there is a need to gain a deeper understanding of ADCs. In this article, we aim to provide a comprehensive overview of the advancements in ADCs. The contents of this article include the structure and mechanism of action, an analysis of recent clinical trials, and expected future clinical questions. This article also focuses on uterine sarcoma, which is not often highlighted as a target for ADC treatment.
尽管近期癌症治疗取得了进展，但子宫恶性肿瘤（癌和肉瘤）的预后仍需进一步改善。抗体药物偶联物（ADC）已成为一类新型抗癌治疗药物，多种ADC已被批准用于其他类型的癌症。2024年，曲妥珠单抗德鲁昔单抗获得美国食品药品监督管理局批准用于多种癌症类型，成为首个获批用于治疗子宫恶性肿瘤的ADC。目前许多ADC正在子宫恶性肿瘤中进行研究，因此有必要更深入地了解ADC。在本文中，我们旨在全面概述ADC的进展。本文内容包括其结构和作用机制、近期临床试验分析以及未来可能出现的临床问题。本文还重点关注子宫肉瘤，它通常未被视为ADC治疗的靶点。
